Target Price | $4.77 |
Price | $3.42 |
Potential |
39.38%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Xeris Pharmaceuticals Inc 2025 .
The average Xeris Pharmaceuticals Inc target price is $4.77.
This is
39.38%
register free of charge
$6.60
92.98%
register free of charge
$3.00
12.28%
register free of charge
|
|
A rating was issued by 6 analysts: 5 Analysts recommend Xeris Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Xeris Pharmaceuticals Inc stock has an average upside potential 2025 of
39.38%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 163.91 | 199.70 |
48.67% | 21.83% | |
EBITDA Margin | -18.82% | -10.92% |
69.39% | 41.98% | |
Net Margin | -40.91% | -30.89% |
56.76% | 24.49% |
6 Analysts have issued a sales forecast Xeris Pharmaceuticals Inc 2024 . The average Xeris Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Xeris Pharmaceuticals Inc EBITDA forecast 2024. The average Xeris Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Xeris Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Xeris Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.45 | -0.41 |
35.71% | 8.89% | |
P/E | negative | |
EV/Sales | 3.56 |
5 Analysts have issued a Xeris Pharmaceuticals Inc forecast for earnings per share. The average Xeris Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Xeris Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Xeris Pharmaceuticals Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.